NovoCure (NVCR)

• Market cap: $1.9B
• 1 day: -1.68%
• 5 days: -7.15%
• 1 month: -4.83%
• 3 months: -41.58%
• 6 months: 17.66%
• Year to date: -41.58%
• 1 year: 13.11%
• 5 years: -72.85%
• 10 years: -4.16%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Employees: 1,453

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

289% more call options, than puts

Call options by funds: $68.8M | Put options by funds: $17.7M

150% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 5 (+3) [Q4]

87% more capital invested

Capital invested by funds: $1.46B [Q3] → $2.73B (+$1.27B) [Q4]

54% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 35

7% more funds holding

Funds holding: 222 [Q3] → 237 (+15) [Q4]

2.09% less ownership

Funds ownership: 86.69% [Q3] → 84.6% (-2.09%) [Q4]

16% less repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 77

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $38 117% upside
• Avg. target: $38 117% upside
• High target: $38 117% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Emily Bodnar 20% 1-year accuracy 33 / 165 met price target

117% upside $38

Buy Reiterated

14 Jan 2025